ATE473762T1 - Ein impfstoff - Google Patents

Ein impfstoff

Info

Publication number
ATE473762T1
ATE473762T1 AT06809961T AT06809961T ATE473762T1 AT E473762 T1 ATE473762 T1 AT E473762T1 AT 06809961 T AT06809961 T AT 06809961T AT 06809961 T AT06809961 T AT 06809961T AT E473762 T1 ATE473762 T1 AT E473762T1
Authority
AT
Austria
Prior art keywords
hsp
antigenic
antigenic molecule
covalently
vaccine
Prior art date
Application number
AT06809961T
Other languages
English (en)
Inventor
Mustoori Sairam
Anju Bansal
Kumari Sarada Surya
Piyush Paliwal
Original Assignee
Defence Res & Dev Organisation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defence Res & Dev Organisation filed Critical Defence Res & Dev Organisation
Application granted granted Critical
Publication of ATE473762T1 publication Critical patent/ATE473762T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06809961T 2005-10-04 2006-10-04 Ein impfstoff ATE473762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2650DE2005 2005-10-04
IN2648DE2005 2005-10-04
PCT/IN2006/000396 WO2007039917A1 (en) 2005-10-04 2006-10-04 A vaccine

Publications (1)

Publication Number Publication Date
ATE473762T1 true ATE473762T1 (de) 2010-07-15

Family

ID=37546799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809961T ATE473762T1 (de) 2005-10-04 2006-10-04 Ein impfstoff

Country Status (5)

Country Link
US (1) US8241645B2 (de)
EP (1) EP1931389B1 (de)
AT (1) ATE473762T1 (de)
DE (1) DE602006015491D1 (de)
WO (1) WO2007039917A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365726B (es) 2013-08-24 2019-06-11 Bharat Biotech Int Ltd Vacuna bacteriana y metodos para la fabricacion de la misma.
CN103995126B (zh) * 2014-04-18 2015-10-14 中国农业大学 一种检测鸡白痢沙门氏菌抗体的elisa试剂盒

Also Published As

Publication number Publication date
US20100196416A1 (en) 2010-08-05
EP1931389B1 (de) 2010-07-14
US8241645B2 (en) 2012-08-14
DE602006015491D1 (de) 2010-08-26
WO2007039917A1 (en) 2007-04-12
EP1931389A1 (de) 2008-06-18

Similar Documents

Publication Publication Date Title
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
EA202192390A1 (ru) Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
ATE539767T1 (de) Adjuvans auf basis von polyinosinsäure/polycytidylsäure
ES2562157T3 (es) Vacuna multiepitópica contra los cánceres asociados con Her2/neu
JP2014503172A5 (de)
JP2007538044A5 (de)
EP1917033A4 (de) Virusähnliche partikel als paramyxovirus-impfstoffe
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
MX366206B (es) Vacuna de antígeno micobacteriano.
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
CR9269A (es) Vacunas orales para peces
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
SE0201701D0 (sv) Treatment of epithelial tumors and infections
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
NO20071030L (no) Immunogene komplekser, metoder for fremstilling derav og bruk av samme i farmasoytiske sammensetninger.
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
DE602006015491D1 (de) Ein impfstoff
US20180161425A1 (en) Novel protein structure used for efficient antibody production in immunization
Shyam et al. Protective efficacy of calcium phosphate nanoparticle adsorbed bivalent subunit vaccine of Pasteurella multocida against homologous challenge in mice
WO2009094006A3 (en) Bordetella outer-membrane protein antigens and methods of making and using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties